Advanced search

Online first
Review paper
Published online: 2024-12-31

open access

View PDF Download PDF file
Page views 282
Article views/downloads 166
Get Citation

Connect on Social Media

Connect on Social Media

Progress in pain management with opioid analgesics: focus on tapentadol, cebranopadol, and oxycodone with naloxone

Renata Zajączkowska1, Wojciech Leppert23, Jerzy Wordliczek4
DOI: 10.5603/pmp.103869

Abstract

Opioids are the strongest analgesics available in medicine and they are used when non-opioid analgesics are ineffective. However, they may cause side effects that may limit their use and therapeutic effect. Therefore, newer opioids with limited adverse effects while preserving analgesic efficacy may have a prominent role in the pharmacotherapy of patients with severe pain intensity. This narrative review focuses on three opioids (tapentadol, cebranopadol, and oxycodone/naloxone) that display different pharmacodynamic and pharmacokinetic properties compared to widely used opioids with the provision of effective analgesia and fewer adverse effects. It highlights a need for an individual and tailored approach to address patient needs regarding management of patients with pain and minimizing adverse effects which ultimately preserves possible highest patients and caregivers quality of life.

Keywords: cebranopadolopioid analgesicsoxycodone/naloxonepaintapentadol

Article available in PDF format

View PDF Download PDF file

References

  1. Abdel Shaheed C, Hayes C, Maher CG, et al. Opioid analgesics for nociceptive cancer pain: a comprehensive review. CA Cancer J Clin. 2024; 74(3): 286–313.
    CrossRefPubMed
  2. Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol. 2023; 41(4): 914–930.
    CrossRefPubMed
  3. Zawilska JB, Adamowicz P, Kurpeta M, et al. Non-fentanyl new synthetic opioids — an update. Forensic Sci Int. 2023; 349: 111775.
    CrossRefPubMed
  4. Schröder W, Vry JDe, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010; 14(8): 814–821.
    CrossRefPubMed
  5. Schröder W, Lambert DG, Ko MC, et al. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol. 2014; 171(16): 3777–3800.
    CrossRefPubMed
  6. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag. 2009; 5(3): 145–151.
    CrossRefPubMed
  7. Schröder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011; 337(1): 312–320.
    CrossRefPubMed
  8. Zajączkowska R, Przewłocka B, Kocot-Kępska M, et al. Tapentadol — a representative of a new class of MOR-NRI analgesics. Pharmacol Rep. 2018; 70(4): 812–820.
    CrossRefPubMed
  9. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265–276.
    CrossRefPubMed
  10. Kneip C, Terlinden R, Beier H, et al. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67–75.
    CrossRefPubMed
  11. Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010; 30(1): 25–34.
    CrossRefPubMed
  12. Mangold B, Oh C, Jaeger D, et al. The pharmacokinetics of tapentadol are not affected by omeprazole: results of a 2-way crossover drug-interaction study in healthy subjects. Pain Pract. 2007; Suppl. 1: 55.
  13. Smit J, Oh C, Mangold B. Effects of metoclopramide on tapentadol pharmacokinetics: results of an open-label, cross-over, drug-drug interaction study. J Clin Pharmacol. 2009; 49: 1104.
  14. Janssen Pharmaceuticals Inc. Nucynta ER tapentadol extended-release oral tablets C–II: prescribing information. https://www.nucynta.com/hcp/er/mechanism-of-action (6.12.2024).
  15. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 2009; 31(12): 2804–2818.
    CrossRefPubMed
  16. Biondi DM, Xiang J, Etropolski M, et al. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015; 11(5): 393–403.
    CrossRefPubMed
  17. Pierce DM, Shipstone E. Pharmacology update: tapentadol for neuropathic pain. Am J Hosp Palliat Care. 2012; 29(8): 663–666.
    CrossRefPubMed
  18. Hartrick C, Rozek R. Tapentadol in pain management. CNS Drugs. 2011; 25(5): 359–370.
    CrossRef
  19. Hartrick CT. Tapentadol immediate-release for acute pain. Expert Rev Neurother. 2010; 10(6): 861–869.
    CrossRefPubMed
  20. Viscusi ER, Allard R, Sohns M, et al. Tapentadol immediate release for moderate to severe acute post-surgery pain. J Opioid Manag. 2019; 15(1): 51–67.
    CrossRefPubMed
  21. D'Amato T, Martorelli F, Fenocchio G, et al. Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study. J Exp Orthop. 2019; 6(1): 36.
    CrossRefPubMed
  22. Bagaphou TC, Cerotto V, Gori F. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study. Eur Rev Med Pharmacol Sci. 2019; 23(4 Suppl): 14–20.
    CrossRefPubMed
  23. Gálvez R, Schäfer M, Hans G, et al. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013; 30(3): 229–259.
    CrossRefPubMed
  24. Sánchez Del Águila MJ, Schenk M, Kern KU, et al. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther. 2015; 37(1): 94–113.
    CrossRefPubMed
  25. Rinonapoli G, Coaccioli S, Panella L. Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence. J Pain Res. 2019; 12: 1529–1536.
    CrossRefPubMed
  26. Marinangeli F, Evangelista M, Finco G. Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option. Eur Rev Med Pharmacol Sci. 2019; 23(4 Suppl): 5–13.
    CrossRefPubMed
  27. Aurilio C. Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study. Eur Rev Med Pharmacol Sci. 2019; 23(4 Suppl): 40–44.
    CrossRefPubMed
  28. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151–162.
    CrossRefPubMed
  29. Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract. 2016; 16(5): 600–619.
    CrossRefPubMed
  30. Ueberall MA, Mueller-Schwefe GHH. Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J Pain Res. 2016; 9: 1001–1020.
    CrossRefPubMed
  31. Borja MB. Tapentadol for the management of neuropathic pain from oxaliplatin chemotherapy. Am J Int Med. 2014; 2(6): 1–4.
  32. Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019; 12: 1537–1551.
    CrossRefPubMed
  33. Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014; 17(4): 329–343.
    PubMed
  34. Brunetti GA, Palumbo G, Morano GS, et al. Tapentadol PR for pain syndromes in real life patients with hematological malignancy. Cardiovasc Hematol Agents Med Chem. 2016; 14(1): 68–74.
    CrossRefPubMed
  35. Coluzzi F, Raffa RB, Pergolizzi J, et al. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015; 8: 229–238.
    CrossRefPubMed
  36. Rosario M, Francesco R, Sergio F, et al. Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. Support Care Cancer. 2016; 24(10): 4451–4455.
    CrossRefPubMed
  37. Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019; 12: 1553–1560.
    CrossRefPubMed
  38. Mercadante S. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Curr Med Res Opin. 2017; 33(11): 1965–1969.
    CrossRefPubMed
  39. Wiffen PJ, Derry S, Naessens K, et al. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015; 2015(9): CD011460.
    CrossRefPubMed
  40. Dickenson AH, Kress HG. Tapentadol: a new option for the treatment of cancer and noncancer pains. J Pain Res. 2019; 12: 1509–1511.
    CrossRefPubMed
  41. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010; 10(5): 416–427.
    CrossRefPubMed
  42. Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin. 2011; 27(10): 1907–1930.
    CrossRefPubMed
  43. Biondi D, Xiang J, Etropolski M, et al. A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies. J Pain. 2011; 12(4 Suppl.): P55.
  44. Biondi DM, Xiang J, Etropolski M, et al. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin Drug Investig. 2014; 34(8): 565–576.
    CrossRefPubMed
  45. Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc). 2009; 45(7): 483–496.
    CrossRefPubMed
  46. Takemura M, Niki K, Okamoto Y, et al. Comparison of the effects of OPRM1 A118G polymorphism using different opioids: a prospective study. J Pain Symptom Manage. 2024; 67(1): 39–49.e5.
    CrossRefPubMed
  47. Toll L, Cal´o G, Cox BM. et al. Opioid receptors, introduction. IUPHAR/ BPS Guide to pharmacology. http://www. guidetopharmacology.org/GRAC/ Family Introduction Forward? familyId550 (4.11.2024).
  48. Tzschentke TM, Linz K, Koch T, et al. Cebranopadol: a novel first-in-class potent analgesic acting via NOP and opioid receptors. Handb Exp Pharmacol Springer Nature Switzerland AG. 2019; 254: 367–398.
    CrossRefPubMed
  49. Linz K, Christoph T, Tzschentke TM, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014; 349(3): 535–548.
    CrossRefPubMed
  50. Raffa RB, Burdge G, Gambrah J, et al. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. J Clin Pharm Ther. 2017; 42(1): 8–17.
    CrossRefPubMed
  51. Schunk S, Linz K, Hinze C, et al. Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol. ACS Med Chem Lett. 2014; 5(8): 857–862.
    CrossRefPubMed
  52. Ciccocioppo R, Angeletti S, Sanna PP, et al. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol. 2000; 404(1–2): 153–159.
    CrossRefPubMed
  53. Kotlinska J, Dylag T, Rafalski P, et al. Influence of nociceptin(1-17) fragments and its tyrosine-substituted derivative on morphine-withdrawal signs in rats. Neuropeptides. 2004; 38(5): 277–282.
    CrossRefPubMed
  54. Lutfy K, Hossain SM, Khaliq I, et al. Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats. Br J Pharmacol. 2001; 134(3): 529–534.
    CrossRefPubMed
  55. Dahan A, Boom M, Sarton E, et al. Respiratory effects of the nociceptin/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers. Anesthesiology. 2017; 126(4): 697–707.
    CrossRefPubMed
  56. Göhler K, Sokolowska M, Schoedel KA, et al. Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study. J Clin Psychopharmacol. 2019; 39(1): 46–56.
    CrossRefPubMed
  57. Christoph A, Eerdekens MH, Kok M, et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017; 158(9): 1813–1824.
    CrossRefPubMed
  58. Eerdekens MH, Kapanadze S, Koch ED, et al. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. Eur J Pain. 2019; 23(3): 577–588.
    CrossRefPubMed
  59. Scholz A, Bothmer J, Kok M, et al. Cebranopadol: a novel, first-in-class, strong analgesic: results from a randomized phase iia clinical trial in postoperative acute pain. Pain Physician. 2018; 21(3): E193–E206.
    PubMed
  60. Kleideiter E, Piana C, Wang S, et al. Clinical pharmacokinetic characteristics of cebranopadol, a novel first-in-class analgesic. Clin Pharmacokinet. 2018; 57(1): 31–50.
    CrossRefPubMed
  61. Eerdekens M, Koch ED, Kok M, et al. Cebranopadol, a novel first-in-class analgesic: efficacy, safety, tolerability in patients with pain due to diabetic peripheral neuropathyn. Postgrad Med. 2016; 128(Suppl. 2): 25.
  62. Koch ED, Kapanadze S, Eerdekens MH, et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks. J Pain Symptom Manage. 2019; 58(3): 390–399.
    CrossRefPubMed
  63. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84(1): 105–109.
    CrossRefPubMed
  64. Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010; 62(4): 578–591.
    CrossRefPubMed
  65. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009; 13(1): 56–64.
    CrossRefPubMed
  66. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008; 62(8): 1159–1167.
    CrossRefPubMed
  67. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002; 23(1): 48–53.
    CrossRefPubMed
  68. Riley J, Eisenberg E, Müller-Schwefe G, et al. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008; 24(1): 175–192.
    CrossRefPubMed
  69. Targinact. The product characteristics. NAPP Pharmaceuticals Limited. https://www.medicines.org.uk/emc/product/503/smpc (5.11.2024).
  70. Reimer K, Hopp M, Zenz M, et al. Meeting the challenges of opioid-induced constipation in chronic pain management — a novel approach. Pharmacology. 2009; 83(1): 10–17.
    CrossRefPubMed
  71. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010; 160(4): 919–930.
    CrossRefPubMed
  72. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain — results from a large observational study. Expert Opin Pharmacother. 2012; 13(3): 299–311.
    CrossRefPubMed
  73. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012; 26(1): 50–60.
    CrossRefPubMed
  74. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011; 65(4): 472–478.
    CrossRefPubMed
  75. Kuusniemi K, Zöllner J, Sjövall S, et al. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice. J Int Med Res. 2012; 40(5): 1775–1793.
    CrossRefPubMed
  76. Comelon M, Wisloeff-Aase K, Raeder J, et al. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy. Acta Anaesthesiol Scand. 2013; 57(4): 509–517.
    CrossRefPubMed
  77. Kokki M, Kuronen M, Naaranlahti T, et al. Opioid-Induced bowel dysfunction in patients undergoing spine surgery: comparison of oxycodone and oxycodone-naloxone treatment. Adv Ther. 2017; 34(1): 236–251.
    CrossRefPubMed
  78. Haeseler G, Schaefers D, Prison N, et al. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone. BMC Anesthesiol. 2017; 17(1): 91.
    CrossRefPubMed
  79. Leppert W. The place of oxycodone/naloxone in chronic pain management. Contemp Oncol (Pozn). 2013; 17(2): 128–133.
    CrossRefPubMed
  80. Dupoiron D, Stachowiak A, Loewenstein O, et al. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Eur J Pain. 2017; 21(9): 1485–1494.
    CrossRefPubMed
  81. Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011; 19(9): 1471–1472.
    CrossRefPubMed
  82. Kang JH, Lee GW, Shin SH, et al. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage. 2013; 46(2): e15–e17.
    CrossRefPubMed
  83. Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin. 2014; 30(6): 1139–1151.
    CrossRefPubMed
  84. Dunlop W, Uhl R, Khan I, et al. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012; 15(3): 564–575.
    CrossRefPubMed
  85. Goeree R, Goeree J. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. J Med Econ. 2016; 19(3): 277–291.
    CrossRefPubMed
  86. Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Pract. 2016; 16(5): 580–599.
    CrossRefPubMed
  87. Thakur D, Dickerson S, Kumar Bhutani M, et al. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review. Clin Ther. 2015; 37(1): 212–224.
    CrossRefPubMed
  88. Fallon M, Giusti R, Aielli F, et al. ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv166–iv191.
    CrossRefPubMed
  89. Larkin PJ, Cherny NI, La Carpia D, et al. ESMO Guidelines Committee. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv111–iv125.
    CrossRefPubMed
  90. Leppert W, et al. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets. 2014; 15(1): 124–135.
    CrossRefPubMed
  91. Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-Induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017; 18(10): 1837–1863.
    CrossRefPubMed
  92. Morlion BJ, Mueller-Lissner SA, Vellucci R, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract. 2018; 18(5): 647–665.
    CrossRefPubMed
  93. Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015; 23(3): 823–830.
    CrossRefPubMed
  94. Bantel C, Tripathi SS, Molony D, et al. Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study. Clin Exp Gastroenterol. 2018; 11: 57–67.
    CrossRefPubMed
  95. Gatti A, Casali M, Lazzari M, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther. 2013; 30(1): 41–59.
    CrossRefPubMed
  96. Huang L, Zhou JG, Zhang Yu, et al. Opioid-Induced constipation relief from fixed-ratio combination prolonged-release oxycodone/naloxone compared with oxycodone and morphine for chronic nonmalignant pain: a systematic review and meta-analysis of randomized controlled trials. J Pain Symptom Manage. 2017; 54(5): 737–748.
    CrossRefPubMed
  97. Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019; 20(5): 511–522.
    CrossRefPubMed
  98. Le BH, Aggarwal G, Douglas C, et al. Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: challenges in the context of hepatic impairment. Asia Pac J Clin Oncol. 2022; 18(1): 13–18.
    CrossRefPubMed
  99. Formenti P, Umbrello M, Pignataro M, et al. Managing severe cancer pain with oxycodone/naloxone treatment: a literature review update. J Pers Med. 2024; 14(5).
    CrossRefPubMed
  100. Barrachina J, Margarit C, Muriel J, et al. Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study. Sci Rep. 2022; 12(1): 10126.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note